💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Nivolumab

CHEMBL2108738 Phase 4 Approved Antibody
Half-Life
27 days
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A checkpoint inhibitor immunotherapy that removes a brake on the immune system, allowing T-cells to recognize and attack cancer cells.

Therapeutic Areas

Age-Related Macular Degeneration Alzheimer's Disease Anesthesiology Asthma Atopic Dermatitis Atrial Fibrillation Benign Prostatic Hyperplasia Bipolar Disorder Bladder Cancer Breast Cancer Cardiovascular Disease Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Chronic Pain Colorectal Cancer Deep Vein Thrombosis / Pulmonary Embolism Dermatology Endocrinology Endometriosis Epilepsy Gastroenterology Gastroesophageal Reflux Disease Generalized Anxiety Disorder Glaucoma Gout Heart Failure Hematology Hepatitis C Hepatology HIV/AIDS Hyperlipidemia Hypertension Immunology Infectious Disease Inflammatory Bowel Disease Insomnia Leukemia Lymphoma Major Depressive Disorder Malaria Melanoma Migraine Multiple Sclerosis Nephrology Neurology Non-Alcoholic Fatty Liver Disease Non-Small Cell Lung Cancer Obesity Obstetrics & Gynecology Oncology Ophthalmology Osteoporosis Ovarian Cancer Pain Management Pancreatic Cancer Parkinson's Disease Prostate Cancer Psoriasis Psychiatry Respiratory Disease Rheumatoid Arthritis Rheumatology Schizophrenia Stroke Systemic Lupus Erythematosus Thyroid Cancer Transplant Medicine Tuberculosis Type 2 Diabetes Urology

Drug Classes

L — L - Antineoplastic and Immunomodulating Agents

Mechanism of Action

Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics (PK)

Half-Life 27 days

Pharmacodynamics (PD)

Mechanism

Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A checkpoint inhibitor immunotherapy that removes a brake on the immune system, allowing T-cells to recognize and attack cancer cells.

Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Key pharmacokinetic parameters for Nivolumab: Half-life: 27 days.

Yes, Nivolumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

ADME Journey →

Related Drugs

Same Drug Class

Adalimumab Antibody Afatinib Small molecule Atezolizumab Antibody Baricitinib Small molecule
{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108738. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.